VetMedIMHA in dogs: glucocorticoid alone vs glucocorticoid plus a second immunosuppressive agent — MAYBE (weak evidence)
In dogs with immune-mediated haemolytic anaemia, does glucocorticoid plus a second immunosuppressive agent (ciclosporin, azathioprine, or mycophenolate) vs glucocorticoid alone improve survival?
Shelf #368 · gate-verified and approved by the developer
MAYBE (weak evidence): No randomised trial answers this question, and the best comparative evidence — a 222-dog retrospective cohort (Piek 2011) — found adding azathioprine to prednisolone made no difference to survival (the treatment made no difference): 1-year survival was 64% (95% CI 54-77%) on prednisolone alone versus 69% (95% CI 59-80%) on prednisolone + azathioprine, a non-significant 5-point gap from a non-randomised comparison in which the combination group started sicker (lower platelet counts, longer-standing signs). For mycophenolate, a retrospective comparison (Wang 2013) found glucocorticoid + mycophenolate performed similarly to other two-drug protocols — but only 3 dogs in that series received glucocorticoids alone, so it cannot test the shelf question directly. The 2013 systematic review of IMHA treatment (Swann & Skelly) judged the overall quality of published evidence poor and drew no firm conclusion in favour of any second agent. Tier C (survival claim). Adding a second immunosuppressant for every IMHA dog is therefore an unproven habit, not an evidence-based standard; the authors of the cohort study themselves call for a blinded randomised trial. Drafted Nov 10, 2026 (VetMed build, topic #368); all figures from abstracts fetched and verified at drafting.
Piek 2011: prednisolone + azathioprine vs prednisolone alone in 222 dogs — 1-year survival 69% vs 64%, no significant difference
Retrospective cohort study (record's own title wording; publication type: Comparative Study)
Who: Dogs: 222 dogs with idiopathic immune-mediated haemolytic anaemia (haematocrit lower than 0.30 L/L and either a positive Coombs' test or spherocytosis, with no evidence of diseases that could trigger IMHA), treated at referral level — 149 dogs under a prednisolone + azathioprine protocol (AP) and 73 under a prednisolone-alone protocol (P).
Result: At study entry the two groups were comparable, except that thrombocyte counts were significantly lower and clinical signs had been present significantly longer in the AP protocol group. No significant difference in survival was found between the two groups: the 1-year survival was 64% (95% CI 54-77%) in the P protocol group and 69% (95% CI 59-80%) in the AP protocol group (the treatment made no difference). The authors conclude azathioprine would appear not to be beneficial as standard treatment for all cases of IMHA, and that a blinded, randomized clinical trial is needed to establish whether outcome differs with the two protocols.
Watch out: Retrospective and non-randomised: protocol choice was not random, and the combination group was measurably sicker at entry (lower platelet counts, longer duration of signs), so confounding by indication could hide a benefit — or manufacture the small numerical gap. Randomisation and blinding are not established for this claim-carrying record. The record tests azathioprine specifically; it says nothing direct about ciclosporin or mycophenolate as the second agent.
Piek CJ, van Spil WE, Junius G, Dekker A. Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anemia: a retrospective cohort study. BMC Vet Res. 2011;7:15. PMID: 21489250. Registry ID: none in the record. MeSH: Anemia, Hemolytic, Autoimmune · Animals · Azathioprine · Blood Platelets · Cohort Studies · Dog Diseases · Dogs · Drug Therapy, Combination · Female · Fibrinogen · Immunosuppressive Agents · Kaplan-Meier Estimate · Male · Partial Thromboplastin Time · Prednisolone · Prothrombin Time · Retrospective Studies
Wang 2013: glucocorticoid + mycophenolate vs other two-drug protocols — no difference in discharge, 30-day or 60-day survival
Retrospective comparison of two-drug protocols (publication type: Journal Article; record describes a retrospective study of medical case records)
Who: Dogs: 64 dogs with idiopathic immune-mediated haemolytic anaemia in a retrospective case-record study — 52 dogs received glucocorticoids plus an additional immunosuppressive drug (30 mycophenolate mofetil, 15 cyclosporine, 6 azathioprine, 1 human immunoglobulin; 7 received two additional drugs), 3 received glucocorticoids alone, and 2 were euthanased without treatment.
Result: There was no significant difference in the discharge rate, 30-day or 60-day survival rates between the mycophenolate mofetil group (glucocorticoids + mycophenolate, n = 30) and the combined group (glucocorticoids + other two-drug protocols) (Fisher's exact; P = 0.272, 0.518, 1.000, respectively) (the treatment made no difference). The sole adverse event observed in the mycophenolate group was diarrhoea (n = 5). The authors conclude mycophenolate appears safe in dogs with IMHA and that glucocorticoids + mycophenolate has similar efficacy to alternate immunosuppressive protocols.
Watch out: This card compares second agents against each other, not against glucocorticoid alone: only 3 dogs received glucocorticoids alone, far too few to test the shelf question, so the card is context for mycophenolate/ciclosporin/azathioprine interchangeability, not evidence on whether any second agent helps. Retrospective, non-randomised, and short-horizon (60 days) in a disease where the cohort study above reports 1-year outcomes.
Wang A, Smith JR, Creevy KE. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011). J Small Anim Pract. 2013;54(8):399-404. PMID: 23879827. Registry ID: none in the record. MeSH: Anemia, Hemolytic, Autoimmune · Animals · Anti-Inflammatory Agents, Non-Steroidal · Azathioprine · Cyclosporine · Diarrhea · Dog Diseases · Dogs · Drug Therapy, Combination · Female · Glucocorticoids · Immunoglobulins · Immunosuppressive Agents · Male · Mycophenolic Acid · Retrospective Studies
Swann & Skelly 2013: systematic review of IMHA treatment evidence — quality poor, no firm conclusions possible
Systematic review (record's own title wording; publication type: Systematic Review)
Who: Dogs: dogs with immune-mediated haemolytic anaemia as covered by the published treatment literature — a systematic review that searched for and assessed all relevant treatment articles against stated criteria (no new animals enrolled).
Result: The overall quality of published evidence was poor, with many articles failing to provide details of the enrollment, treatment, monitoring, and assessment stages of the study process. In view of this, firm conclusions cannot be drawn regarding the treatment of this disease and further research of a higher quality is required.
Watch out: A systematic review is only as strong as its underlying studies, and here the reviewers themselves found them weak — this card supports the MAYBE (weak evidence) stamp rather than any treatment ranking. It predates later consensus guidance and any subsequent trials, so it describes the evidence base as of 2013.
Swann JW, Skelly BJ. Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med. 2013;27(1):1-9. PMID: 23279007. Registry ID: none in the record. MeSH: Anemia, Hemolytic, Autoimmune · Animals · Anticoagulants · Dog Diseases · Dogs · Heparin · Immunosuppressive Agents
Synthesis: the second-agent habit is unproven — the one direct comparison found no survival benefit
Synthesis
Who: Synthesis of the cards above: Piek 2011 (retrospective cohort, 222 dogs with idiopathic IMHA), Wang 2013 (retrospective protocol comparison, 64 dogs) and Swann & Skelly 2013 (systematic review of the IMHA treatment literature).
Result: Every comparative strand points the same way: prednisolone + azathioprine did not beat prednisolone alone on 1-year survival (69% vs 64%, not significant); mycophenolate-based and other two-drug protocols did not differ from each other on short-term survival; and the systematic review of the whole field concluded the evidence is too poor for firm conclusions. Nothing here shows a second immunosuppressive agent improves survival in canine IMHA, and the added drugs carry their own toxicity and cost (azathioprine is described in the cohort record as potentially toxic and carcinogenic). Selective use in individual severe or relapsing cases remains a clinical judgement; routine addition for all cases is not evidence-based.
Watch out: Absence of evidence is not proof of absence of benefit: all carded comparisons are retrospective and confounded by indication (sicker dogs get more drugs), and no carded record isolates ciclosporin as the added agent against glucocorticoid alone. A blinded randomised trial — called for by Piek 2011 itself — could still change this stamp.
Synthesis of Piek CJ et al. PMID: 21489250, Wang A et al. PMID: 23879827, and Swann JW, Skelly BJ. PMID: 23279007. Registry ID as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.